Safety Evaluation of Bioactive Glass Based Bone Cement Combined With Ultrasound in Implantation for Metastatic Bone Tumors (SE-BGCU-MBT)
Safety Evaluation of Bioactive Glass-Based Bone Cement Combined With Ultrasound in Implantation for Metastatic Bone Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Shanghai general hospital
- Phone Number: +86-021-63240090
- Email: 191434914@qq.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1.Age between 18 and 80 years (inclusive), regardless of gender; 2. Patients with advanced cancer, presenting with intractable pain due to clinically, radiologically and pathologically confirmed pelvic metastases; 3. Osteolytic lesions primarily located in the periacetabular or non-periacetabular regions; 4. Expected survival of more than 1 year; 5. Voluntarily agree to participate in this clinical trial, and the subject and/or their legal guardian is willing and able to provide written informed consent; 6. Demonstrates good compliance, is willing to follow medical advice, and is able to attend all required follow-up visits as specified in the protocol.
Exclusion Criteria:
- 1. Relative surgical contraindications, such as pelvic discontinuity or fracture displacement > 5 mm; 2. Poor general health status with an estimated survival of less than 3 months; 3. Destruction of the inner iliac cortex associated with soft tissue masses affecting vital organs, nerves, or blood vessels; 4. Presence of active systemic infection; 5. Previous history of bone cement injection at the target lesion site; 6. Severe hepatic or renal dysfunction (Child-Pugh class C, eGFR < 30 mL/min); 7. Coagulopathy or bleeding diathesis; 8. Known hypersensitivity or allergy to bone cement components; 9. Poor adherence, unwilling or unable to comply with postoperative treatment and/or rehabilitation regimens; 10. Patients who are mentally incompetent or unable to understand the requirements of study participation; 11. Unable to attend follow-up visits at the study institution; 12. Participation in another clinical trial within 3 months prior to enrollment in this study; 13. Pregnant or breastfeeding women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: BG-Bone Cement + Ultrasound Treatment Group
|
Bioactive Glass Bone Cement + Ultrasound
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse Event/Adverse Reaction Incidence Rate
Time Frame: 12 months postoperatively
|
12 months postoperatively
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20251115101641097
- U23A20692 (Other Grant/Funding Number: National Natural Science Foundation of China)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
NCT07190807RecruitingLow Back Pain | Chronic Pain | Chronic Low-back Pain | Leg Pain | Intractable Pain | Chronic Leg Pain
-
NCT07454083Not yet recruitingNon-Cancer Pain,Musculoskeletal Pain,Chronic Pain,Acute Pain
-
NCT00866164Approved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
NCT04640896RecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial Pain
-
NCT03597737CompletedPain, Acute | Pain, Chronic | Oncology
-
NCT05187390RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATS
-
NCT00929188CompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, Splitting
-
NCT04280796CompletedLow Back Pain | Pain, Acute | Pain, Chronic
-
NCT01576978CompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
NCT03727373CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, Cancer
Clinical Trials on Bioactive Glass Bone Cement + Ultrasound
-
NCT00935870CompletedBioactive Glass as Bone Graft Substitute in Operative Treatment of Bone - a 10 Years Follow-up StudySpinal Fusion | Depressed Lateral Condyle Fracture | Benign Bone Tumour Cavity
-
NCT07125846Not yet recruitingTooth Loss | Alveolar Bone Loss | Maxillary Sinus Disease
-
NCT04814160CompletedHorizontal Alveolar Ridge Deficiency
-
NCT07496112Enrolling by invitation
-
NCT07611734Not yet recruitingDental Caries | Tooth Injuries | Primary Tooth Restoration
-
NCT06160505RecruitingChronic Suppurative Otitis Media
-
NCT05974228Not yet recruiting
-
NCT06116513Recruiting